mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics
Source abstract
Abstract
Recent breakthroughs in mRNA therapeutics have transformed vaccine development, largely powered by lipid nanoparticle (LNP) based delivery systems. However, these systems exhibit a strong hepatic tropism, making them suboptimal for targeting extrahepatic organs such as the brain, lungs, pancreas, heart, and tumor tissues critical to non-vaccine therapeutic applications. This review explores next-generation delivery strategies designed to overcome liver centric distribution. We highlight emerging platforms, including pKa-tuned LNPs, polymeric and peptide-based carriers, exosomes, and biomimetic vesicles, along with physical enhancement techniques such as ultrasound, laser, and MRI-guided systems. Nonetheless, researchers are achieving more precise delivery to deep seated tissues by integrating these technologies with targeted ligands and responsive release mechanisms. Applications in oncology, cardiology, pulmonology, and neurology are discussed with a focus on preclinical and early clinical outcomes. Regulatory considerations, including immunogenicity, biodistribution, and manufacturing scalability, are also reviewed. Ultimately, this article presents a forward-looking perspective on engineering safe, organ specific mRNA delivery platforms beyond the liver, enabling the advancement of precision therapeutics. This review will provide a timely and comprehensive overview of innovative strategies to overcome these challenges, focusing on non-vaccine applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The progress and promise of RNA medicine – an arsenal of targeted treatments10.1021/acs.jmedchem.2c00024 ↗
2. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine10.1056/NEJMoa2035389 ↗
3. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine10.1056/NEJMoa2034577 ↗
4. Targeted nonviral delivery of genome editors in vivo
5. Recent advances in nanoparticulate RNA delivery systems
6. Strategies for non-viral vectors targeting organs beyond the liver
7. Drug delivery systems for RNA therapeutics10.1038/s41576-021-00439-4 ↗
8. Advances in oligonucleotide drug delivery10.1038/s41573-020-0075-7 ↗
9. Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system10.1038/s41563-024-02114-5 ↗
10. Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a phase 1/2 clinical study of MRT500510.1016/j.jcf.2023.04.008 ↗
11. Treatment of ischemic neuronal death by introducing brain-derived neurotrophic factor mRNA using polyplex nanomicelle10.1016/j.biomaterials.2021.120681 ↗
12. Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer's disease
13. Progress and prospects of mRNA-based drugs in pre-clinical and clinical trials. Signal Transduct Target Ther · 2024 · 9 · 60
14. Reengineering endogenous targeting lipid nanoparticles (ENDO) for systemic delivery of mRNA to pancreas10.1002/adma.202507657 ↗
15. LNP-mRNA vaccine prevents type 1 diabetes in Non-obese diabetic mice10.1016/j.jconrel.2024.09.020 ↗
16. Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced Obese mice10.1016/j.omtn.2022.04.010 ↗
17. Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery10.1021/acsnano.8b07858 ↗
18. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
19. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA10.1038/mtna.2012.28 ↗
20. Advances in manufacturing technologies for lipid nanoparticles and their implications for RNA delivery
21. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs10.1038/s41565-019-0591-y ↗
22. Therapeutic cancer vaccines: advancements, challenges and prospects10.1038/s41392-023-01674-3 ↗
23. 958 BNT211: a phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors
24. Toxicity of cationic lipids and cationic polymers in gene delivery10.1016/j.jconrel.2006.04.014 ↗
25. The role of lipid components in lipid nanoparticles for vaccines and gene therapy
26. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery10.1002/smtd.201700375 ↗
27. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines10.1016/j.omtn.2019.01.013 ↗
28. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs10.1021/acs.nanolett.5b02497 ↗
29. The biomolecular corona of lipid nanoparticles for gene therapy10.1021/acs.bioconjchem.0c00366 ↗
30. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms10.1038/mt.2010.85 ↗
31. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes
32. A combinatorial library of lipid nanoparticles for cell type‐specific MRNA delivery
33. Ionizable lipids with optimized linkers enable lung-specific, lipid nanoparticle-mediated mRNA delivery for treatment of metastatic lung tumors10.1021/acsnano.4c18636 ↗
34. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing10.1038/s41565-020-0669-6 ↗
35. Transbilayer movement and net flux of cholesterol and cholesterol sulfate between liposomal membranes10.1021/bi00018a025 ↗
36. PEG – a versatile conjugating ligand for drugs and drug delivery systems10.1016/j.jconrel.2014.06.046 ↗
37. Lipid nanoparticles with fine‐tuned composition show enhanced Colon targeting as a platform for mRNA therapeutics
38. Self-assembled mRNA vaccines10.1016/j.addr.2020.12.014 ↗
39. On the role of helper lipids in lipid nanoparticle formulations of siRNA10.1039/C9NR09347H ↗
40. Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes10.1007/s11095-012-0874-6 ↗
41. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage10.1016/j.jconrel.2013.07.026 ↗
42. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals10.1016/j.molimm.2014.06.038 ↗
43. PEGylated liposomes: immunological responses10.1080/14686996.2019.1627174 ↗
44. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines10.1038/s41565-022-01071-x ↗
45. Polymeric vehicles for nucleic acid delivery10.1016/j.addr.2020.06.014 ↗
46. Materials for non-viral intracellular delivery of messenger RNA therapeutics10.1016/j.jconrel.2015.12.032 ↗
47. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers10.1038/s41467-019-11911-5 ↗
48. Poly (ethylene glycol) alternatives in biomedical applications10.1016/j.nantod.2022.101738 ↗
49. Poly (N‐methyl‐N‐vinylacetamide): a strong alternative to PEG for lipid‐based nanocarriers delivering siRNA
50. An integrated polymeric mRNA vaccine without inflammation side effects for cellular immunity–mediated cancer therapy10.1002/adma.202207471 ↗
51. Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes10.1021/jacs.1c09822 ↗
52. Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination10.1016/j.ejpb.2021.03.011 ↗
53. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors10.1016/j.biomaterials.2011.09.061 ↗
54. Surface functionalisation of PLGA nanoparticles for gene silencing10.1016/j.biomaterials.2010.03.069 ↗
55. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response10.1186/s12967-016-1111-6 ↗
56. RNA-based vaccines in cancer immunotherapy10.1155/2015/794528 ↗
57. Delivery of various cargos into cancer cells and tissues via cell-penetrating peptides: a review of the last decade10.3390/pharmaceutics13091391 ↗
58. Cell-penetrating peptides for siRNA delivery to glioblastomas10.1016/j.peptides.2018.04.015 ↗
59. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo10.1093/nar/gkq1299 ↗
60. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells10.1016/j.actbio.2017.06.032 ↗
61. A targeted and stable polymeric nanoformulation enhances systemic delivery of mRNA to tumors10.1016/j.ymthe.2016.10.006 ↗
62. Peptide-mediated delivery of therapeutic mRNA in ovarian cancer10.1016/j.ejpb.2019.05.014 ↗
63. Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine10.1016/j.jconrel.2019.08.002 ↗
64. Polymer–lipid nanoparticles for systemic delivery of mRNA to the lungs10.1002/anie.201608450 ↗
65. The biology, function, and biomedical applications of exosomes10.1126/science.aau6977 ↗
66. Extracellular vesicles as drug delivery systems: why and how?10.1016/j.addr.2020.04.004 ↗
67. Anti-HER2 scFv-directed extracellular vesicle–mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation10.1158/1535-7163.MCT-17-0827 ↗
68. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation10.1038/s41551-019-0485-1 ↗
69. Synthetic transcription factors establish the function of nine amino acid transactivation domains of Komagataella phaffii Mxr110.1016/j.jbc.2025.108211 ↗
70. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment10.1038/s41467-018-03733-8 ↗
71. Linkage between endosomal escape of LNP–mRNA and loading into EVs for transport to other cells10.1038/s41467-019-12275-6 ↗
72. Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity10.1016/j.jbc.2021.101266 ↗
73. Extracellular vesicle-based hybrid systems for advanced drug delivery10.3390/pharmaceutics14020267 ↗
74. Engineering hybrid exosomes by membrane fusion with liposomes
75. Degradable terpolymers with alkyl side chains demonstrate enhanced gene delivery potency and nanoparticle stability10.1002/adma.201204346 ↗
76. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination10.1016/j.biomaterials.2017.02.019 ↗
77. Co-delivery of mRNA with α-galactosylceramide using a new lipopolyplex formulation induces a strong antitumor response upon intravenous administration10.1021/acsomega.9b00489 ↗
78. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells10.1016/j.jconrel.2018.03.035 ↗
79. mRNA therapy for myocardial infarction: a review of targets and delivery vehicles10.3389/fbioe.2022.1037051 ↗
80. Recent advances in erythrocyte membrane-camouflaged nanoparticles for the delivery of anti-cancer therapeutics10.1080/17425247.2022.2108786 ↗
81. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform10.1073/pnas.1106634108 ↗
82. Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance
83. Recent advances in cell membrane coated-nanoparticles as drug delivery systems for tackling urological diseases10.3390/pharmaceutics15071899 ↗
84. ModernaTX, Inc. Repeat-Dose Study of mRNA-3927 in Participants with Cystic Fibrosis (NCT05668741). ClinicalTrials.gov.
85. ModernaTX, Inc. Phase 1/2 Study of Intratumoral mRNA-2752 for relapsed/refractory Lymphoma (NCT05712538). ClinicalTrials.gov.
86. Direct intramyocardial injection of VEGF-A mRNA in patients undergoing coronary artery bypass surgery: a randomized, controlled phase 2 trial10.1016/j.ymthe.2022.11.017 ↗
87. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study10.1016/S0140-6736(23)02268-7 ↗
88. BioNTech · 2024
89. RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics10.1186/s12943-022-01528-6 ↗
90. A phase Ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced Melanoma, non–small cell lung cancer, or bladder cancer10.1016/j.cell.2020.08.053 ↗
91. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination
92. Lung-delivered IL-10 mitigates lung inflammation induced by repeated endotoxin exposures in male mice
93. Rapid generation of circulating and mucosal decoy human ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2
94. mRNA-encoded ACE2 decoy lipid nanoparticles for neutralizing SARS-CoV-2 variants10.1016/j.omtn.2025.102515 ↗
95. Lyophilization provides long-term stability for a lipid nanoparticle–encapsulated mRNA vaccine
96. Development of lyophilized mRNA-LNPs with high stability and transfection efficiency in specific cells and tissues10.1093/rb/rbaf023 ↗
97. Hepatocyte growth factor delivered by nanocomposites for gene therapy of bleomycin-induced pulmonary fibrosis in rats10.2174/1567201819666220613145417 ↗
98. ModernaTX, Inc. Phase 1/2 Study of CAR-T Cell Therapy BNT211 (CLDN6 CAR-T) plus Carvac in Solid Tumors (NCT04503278). ClinicalTrials.gov.
99. Gastrointestinal delivery of mRNA lipid nanoparticles selectively targets the pancreas
100. Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic ductal adenocarcinoma10.1016/j.jconrel.2025.113588 ↗